Breakthrough in Patient and Staff Safety During Cardiac Interventions

Royal Philips ElectronicsRoyal Philips (NYSE: PHG, AEX: PHIA), the Radboud University Nijmegen Medical Centre (Nijmegen, the Netherlands) and Main-Taunus Cardiac Center (Bad Soden, Germany) today announced the results of a clinical study that demonstrate that the safety for patients and clinicians can be significantly enhanced during cardiac interventions. Using Philips' recently introduced AlluraClarity system* with ClarityIQ technology, the doctors of the medical center were, for the first time, able to achieve a 50 percent reduction in X-ray dose while maintaining the excellent image quality needed during image-guided cardiac interventions. The results will be presented during the annual congress of the European Association for Percutaneous Cardiovascular Interventions (EuroPCR), 21 - 24 May in Paris.

The clinical study was designed by Main-Taunus Cardiac Center and conducted at the Radboud University Nijmegen Medical Centre between September and November 2012 involving 39 patients with a BMI range of 20 - 37. During the study, two coronary angiography scans of the same patient were compared: for the first scan conventional interventional X-ray technology was used, while for the second scan Philips' ClarityIQ technology was used. Six independent interventional cardiologists from across Europe (Italy, France, Germany, the Netherlands and Sweden) then evaluated the image quality of these scans, and concluded that compared to conventional X-ray technology, AlluraClarity provided equivalent image quality at 50 percent less X-ray dose.

"We have extensively explored and tested this new technology at our cardiac center," said Prof. Dr. med. N. Reifart, co-author of the study and Director of the Main-Taunus Cardiac Center, Private Clinic Bad Soden. "It now enables us to perform most diagnostic angiographies with at least 50 percent lower radiation levels, equivalent to less than 1 mSv, with similar image quality as in the past."

"Such a significant reduction in X-ray dose benefits both patients and the staff managing their care," said Dr. T.J.F ten Cate, the cardiologist at the Radboud University Nijmegen Medical Centre and responsible for conducting the study. "Now that we are using AlluraClarity, we have become much more conscious about X-ray radiation dose."

The study results represent an important milestone for Philips, showcasing how complex interventional procedures can be performed with a significant reduction in X-ray dose. Last year, Philips announced that it had achieved a breakthrough with the same X-ray technology in endovascular procedures, in collaboration with the St. Antonius Hospital Utrecht/Nieuwegein (the Netherlands), a renowned center of expertise in the field of heart and vascular interventions. A study conducted at the Karolinska University Hospital (Sweden) in the field of neuroradiology demonstrated that AlluraClarity provides equivalent image quality at 73 percent less dose. Additional studies in the field of neuroradiology and electrophysiology are ongoing, with results expected later this year.

"Because of the intrinsic benefits for patients and care providers, there is a clear shift in healthcare from open surgery to minimally-invasive treatments," commented Ronald Tabaksblat, General Manager, Philips Interventional X-Ray. "Live X-ray guidance is typically being used to perform such minimally invasive treatments. Our ClarityIQ technology significantly reduces the X-ray exposure required to produce high quality images, demonstrating that Philips is truly leading the way in improving the delivery of healthcare."

Since its commercial introduction mid-2012, Philips has sold more than 200 AlluraClarity systems in regions such as Asia, Europe, the Middle East and Latin America.

Visit Philips at EuroPCR 2013 at booth #M41 to learn more about this clinical study or to speak with a Philips representative. Dr. T.J.F ten Cate will be giving a presentation at EuroPCR titled: 'Automated image enhancement significantly reduces radiation dosage in coronary angiography with preserved image quality' on Thursday, May 23, 10:57 – 11:05 a.m., in room 241.

Also showcasing at EuroPCR is Philips' new EchoNavigator live image guidance tool and Allura Centron, an addition to the Allura family of interventional solutions. It is a high performance multi-purpose interventional X-ray system for routine procedures.

* Philips AlluraClarity is currently not available for sale in USA, 510(k) pending

About Royal Philips Electronics
Royal Philips Electronics (NYSE: PHG, AEX: PHIA) is a diversified health and well-being company, focused on improving people’s lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2012 sales of EUR 24.8 billion and employs approximately 116,000 employees with sales and services in more than 100 countries. The company is a leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming and oral healthcare.

Most Popular Now

Open Call HORIZON-MISS-2022-CANCER-01-04…

The overall goal of the Mission on Cancer[1] and the Europe's Beating Cancer Plan[2] includes a better quality of life for patients and their families living with, and after, cancer. Project...

Researchers Use AI to Predict Cancer Ris…

An artificial intelligence (AI) tool helps doctors predict the cancer risk in lung nodules seen on CT, according to a new study published in the journal Radiology. Pulmonary nodules appear as...

Insilico Medicine Raises $60 Million in …

Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, announced today that it has completed a $60 million Series D financing from a syndicate of global investors with...

Speech Analysis App Predicts Worsening H…

A voice analysis app used by heart failure patients at home recognises fluid in the lungs three weeks before an unplanned hospitalisation or escalation in outpatient drug treatment. The late...

Siemens Healthineers and Penta Hospitals…

Penta Hospitals International, the largest multi-national hospital chain in Central and Eastern Europe, agreed a strategic partnership with Siemens Healthineers valued at over 30 million euros. Penta Hospitals International operates...

Screening for Diabetic Retinopathy Prove…

Both telemedicine and community screening for diabetic retinopathy (DR) in rural and urban settings are cost-effective in China, and telemedicine screening programs are more cost-effective, according to a study led...

KTU Researchers Investigate the Links Be…

In recent years Alzheimer's disease has been on the rise throughout the world and is rarely diagnosed at an early stage when it can still be effectively controlled. Using artificial...

Researchers Develop Smartphone-Powered M…

A University of Minnesota Twin Cities research team has developed a new microfluidic chip for diagnosing diseases that uses a minimal number of components and can be powered wirelessly by...

Philips' Future Health Index 2022 Report…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the publication of its Future Health Index (FHI) 2022 report: 'Healthcare hits reset: Priorities shift as...

App Detecting Jaundice in Babies a Succe…

A smartphone app that identifies severe jaundice in newborn babies by scanning their eyes could be a life-saver in areas that lack access to expensive screening devices, suggests a study...

InterSystems Wins Data Driven Product of…

InterSystems, a provider of next-generation solutions for enterprise digital transformation to help customers solve the most critical data challenges, has announced it received the prestigious Data Driven Product of the...